Efficacy News and Research

RSS

Many phase II trials overestimate drug efficacy, pose a barrier in drug licensing

Based on a systematic analysis of trials related to rheumatoid arthritis and psoriasis arthritis, a MedUni Vienna study group at the Division of Rheumatology at MedUni Vienna/Vienna General Hospital was able to show that many clinical phase II trials systematically overestimate the efficacy of therapeutics, so that the results of subsequent phase III trials can often be disappointing. Essentially this situation also applies in many other areas.

21 Apr 2020

Mutations in novel coronavirus make it more dangerous

A new report published on the preprint server medRxiv in April 2020 reveals that the novel coronavirus SARS-CoV-2 shows the presence of new mutations acquired within infected human cases, which significantly increase its ability to cause human disease.

20 Apr 2020

HIV-1 and influenza antivirals not effective for treating mild-to-moderate COVID-19 cases

An exploratory randomized, controlled study on the safety and efficacy of either lopinavir/ritonavir (LPV/r) or Arbidol--antivirals that are used in some countries against HIV-1 and to treat influenza , respectively--as treatments for COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, suggests that neither drug improves the clinical outcome of patients hospitalized with mild-to-moderate cases of the disease over supportive care.

20 Apr 2020

Penn Medicine launches convalescent plasma therapy trial for COVID-19 patients

Convalescent plasma therapy for COVID-19 patients -- an experimental approach of giving a transfusion of plasma collected from a donor who has recovered from COVID-19 to a patient with an active infection -- is the focus of a new two-part research initiative at Penn Medicine.

20 Apr 2020

Remdesivir prevents COVID-19 progression to severe pneumonia, animal study shows

A team of scientists at the National Institute of Allergy and Infectious Diseases, which is part of the U.S. National Institutes of Health, has tested the efficacy of remdesivir, a nucleotide analog prodrug with a broad antiviral activity, as a COVID-19 treatment.

20 Apr 2020

How are the interventions against COVID-19 working in Sweden?

In a new study, Swedish researchers speculate the effects of the present intervention strategies on the healthcare system as the COVID-19 pandemic affects the nation. Their study titled, “Intervention strategies against COVID-19 and their estimated impact on Swedish healthcare capacity,” has not been published yet; however, the findings are available as pre-peer-reviewed study at medRxiv.

19 Apr 2020

Research suggests Nelfinavir and Cepharanthine as potential anti-SARS-CoV-2 agents

A new study published in the journal bioRxiv in April 2020 reports the identification of a promising multidrug treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for causing COVID-19 disease. The team predicts that this combination will prevent the virus from reproducing, hence both halting the transmission and progress of the disease.

19 Apr 2020

Computer simulations yield promising vaccine candidate against SARS-CoV-2

In a recent study that appeared on a preprint server bioRxiv, scientists from India designed a multi-epitope peptide-based vaccine that predicted high immunogenic response in the population.

19 Apr 2020

Researchers identify a promising model for testing COVID-19 therapeutics

After comparing how infections from SARS-CoV-2 (which causes COVID-19) and two other human coronaviruses develop in cynomolgus macaques, researchers report that SARS-CoV-2 gives the animals a mild COVID-19-like disease.

18 Apr 2020

A promising antiviral drug to fight COVID-19 pandemic

COVID-19 patients in a clinical trial at Houston Methodist Hospital are responding quickly to the antiviral drug Remdesivir. The trial's criteria allows for the treatment of patients early in their clinical course and, in some cases, at times where they might have otherwise been intubated.

17 Apr 2020

Random testing key to a safe exit from COVID-19 lockdown

The coronavirus disease (COVID019) global pandemic has placed many countries and regions in lockdown. There are thousands of cases reported daily, with the global infection toll topping 2.15 million. How can nations shift from lockdown back to normal daily routines while ensuring there won’t be a second wave of viral infection?

16 Apr 2020

Are overactive immune cells causing COVID-19-related deaths?

While the COVID-19 pandemic is devastating many regions, the world over, a new paper published in the Journal of Experimental Medicine in April 2020 describes the possibility that the critical or very severe cases of COVID-19 are due to the production of neutrophil extracellular traps (NET) due to hyperactivated immune cells.

16 Apr 2020

Scripps Research establishes collaborative global effort to rapidly find drugs against COVID-19

With the COVID-19 pandemic continuing to spread across the globe, Scripps Research has quickly established an international network of collaborating scientific laboratories to leverage ReFRAME, the world's leading drug repurposing collection, to find antiviral compounds against the novel coronavirus.

16 Apr 2020

Drug improves effectiveness of chemotherapy in ovarian cancer patients

An international research team, led by scientists from Mater Research - The University of Queensland, have discovered they can overcome chemotherapy resistance in an ovarian cancer subtype by using low doses of a drug which slows cell growth.

16 Apr 2020

Remdesivir drug stops novel coronavirus from replicating

Scientists from the University of Alberta have published findings that the antiviral drug remdesivir prevents replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by inhibiting RNA replication. The study, published in April 2020 in the Journal of Biological Chemistry, follows on the heels of earlier reports from the same lab in February, showing the drug's effectiveness against the related Middle East Respiratory Syndrome (MERS) virus.

15 Apr 2020

New drug preserves cognitive function in mice after brain irradiation

A study by researchers at the UCLA Jonsson Comprehensive Cancer Center has identified a possible new drug that could help prevent cognitive decline in people who undergo radiation therapy for brain tumors.

15 Apr 2020

Chronic stress can influence the efficacy of radiation therapy, study suggests

Radiation is one of the oldest and most common therapies for cancer, and typically is delivered locally, or to specific targeted sites in the body.

15 Apr 2020

The race is on for a coronavirus vaccine, 70 candidates, 3 at human trial stage

Amid the coronavirus disease (COVID-19) global pandemic that is infecting millions of people across the globe, hope sparks as the World Health Organization (WHO) reports that seventy vaccination trials for the novel coronavirus are underway, with three already at the human trial stage.

14 Apr 2020

New vaccine for Chikungunya reported safe and well-tolerated

A virus-like particle vaccine was shown to be safe and well-tolerated among a healthy adult population living in chikungunya endemic areas, the researchers report in a new study published in the Journal of the American Medical Association (JAMA).

14 Apr 2020

Cost of ‘repurposing’ existing drugs to treat COVID-19

The paper looks at repurposed drugs that might demonstrate efficacy against COVID-19, and if they could be manufactured profitably at very low costs to ensure affordable access to vital treatments for COVID-19 at low prices globally.

13 Apr 2020